A preclinical study described an IL-6-responsive CAR macrophage construct designed to remodel the tumor extracellular matrix and enhance CAR-T cell activity in solid tumor models. The approach couples an IL-6-binding module to a CD147-containing macrophage design, with the company reporting improved tumor killing and prolonged survival in mice. Mechanistically, engineered macrophages increased matrix metalloproteinases such as MMP-2, MMP-9, MMP-11, and MMP-13 upon IL-6 stimulation, intended to improve immune-cell access by changing the tumor microenvironment. In mixed-antigen models, the combination of IL6-CD147 CAR-M and CAR-T reduced tumor burden and increased immune infiltration. The authors noted unresolved questions about how extracellular IL-6 levels decline under combination conditions and stressed that the work remains at the preclinical cell and animal stages. They reported no overt organ histopathology abnormalities at evaluated timepoints, but positioned the findings as requiring longer-term safety assessment before clinical translation. The development adds to a growing push to use engineered myeloid cell systems to overcome microenvironment barriers that limit CAR T performance in solid tumors.